Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Free Cash Flow (2016 - 2025)

Organogenesis Holdings has reported Free Cash Flow over the past 10 years, most recently at $34.8 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $34.8 million for Q4 2025, up 358.92% from a year ago — trailing twelve months through Dec 2025 was -$24.5 million (down 685.73% YoY), and the annual figure for FY2025 was -$24.5 million, down 685.73%.
  • Free Cash Flow for Q4 2025 was $34.8 million at Organogenesis Holdings, up from $844000.0 in the prior quarter.
  • Over the last five years, Free Cash Flow for ORGO hit a ceiling of $40.2 million in Q4 2021 and a floor of -$36.5 million in Q2 2025.
  • Median Free Cash Flow over the past 5 years was $3.8 million (2024), compared with a mean of $1.8 million.
  • Biggest five-year swings in Free Cash Flow: surged 392.24% in 2021 and later crashed 2667.58% in 2025.
  • Organogenesis Holdings' Free Cash Flow stood at $40.2 million in 2021, then plummeted by 151.13% to -$20.6 million in 2022, then soared by 135.47% to $7.3 million in 2023, then grew by 3.92% to $7.6 million in 2024, then soared by 358.92% to $34.8 million in 2025.
  • The last three reported values for Free Cash Flow were $34.8 million (Q4 2025), $844000.0 (Q3 2025), and -$36.5 million (Q2 2025) per Business Quant data.